NI201300045A - Inhibidores de apoptosis y usos de los mismos. - Google Patents

Inhibidores de apoptosis y usos de los mismos.

Info

Publication number
NI201300045A
NI201300045A NI201300045A NI201300045A NI201300045A NI 201300045 A NI201300045 A NI 201300045A NI 201300045 A NI201300045 A NI 201300045A NI 201300045 A NI201300045 A NI 201300045A NI 201300045 A NI201300045 A NI 201300045A
Authority
NI
Nicaragua
Prior art keywords
fragments
apoptosis
pharmaceutical compositions
relates
apoptosis inhibitors
Prior art date
Application number
NI201300045A
Other languages
English (en)
Inventor
Barrere Stéphanie
Nargeot Joël
Lebleu Bernard
Boisguerin Prisca
Piot Christophe
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43880951&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201300045(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Publication of NI201300045A publication Critical patent/NI201300045A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se relaciona con fragmentos de las proteinas DAXX y FADD que inhiben la apoptosis celular, en particular apoptosis celular mediada por el receptor Fas. La invención también se relaciona con derivados de dichos fragmentos anti-apoptóticos, conjugados que comprenden dichos fragmentos, composiciones farmacéuticas que comprenden dichos fragmentos, y con aplicaciones médicas de dichos fragmentos, dirivados, conjugados, y composiciones farmacéuticas de los mismos en el tratamiento o prevención de enfermedades y condiciones asociadas con apoptosis.
NI201300045A 2010-11-18 2013-05-14 Inhibidores de apoptosis y usos de los mismos. NI201300045A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2010/003158 WO2012066376A1 (en) 2010-11-18 2010-11-18 Inhibitors of apoptosis and uses thereof

Publications (1)

Publication Number Publication Date
NI201300045A true NI201300045A (es) 2013-08-01

Family

ID=43880951

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201300045A NI201300045A (es) 2010-11-18 2013-05-14 Inhibidores de apoptosis y usos de los mismos.

Country Status (36)

Country Link
US (1) US9814758B2 (es)
EP (2) EP2982685B1 (es)
JP (1) JP6204828B2 (es)
KR (2) KR102017645B1 (es)
CN (2) CN106188271B (es)
AU (1) AU2011331103B2 (es)
BR (1) BR112013012362A2 (es)
CA (2) CA2816827C (es)
CL (1) CL2013001411A1 (es)
CO (1) CO6700879A2 (es)
CR (1) CR20130190A (es)
CY (1) CY1118022T1 (es)
DK (1) DK2640739T3 (es)
EA (1) EA027336B1 (es)
ES (2) ES2653734T3 (es)
GE (1) GEP201606514B (es)
GT (1) GT201300117A (es)
HR (1) HRP20151165T1 (es)
HU (1) HUE026150T2 (es)
IL (2) IL226005B (es)
MA (1) MA34670B1 (es)
ME (1) ME02291B (es)
MX (1) MX345594B (es)
MY (1) MY170604A (es)
NI (1) NI201300045A (es)
NZ (1) NZ610620A (es)
PH (1) PH12013500843A1 (es)
PL (1) PL2640739T3 (es)
PT (1) PT2640739E (es)
RS (1) RS54422B1 (es)
RU (1) RU2582247C2 (es)
SG (1) SG190681A1 (es)
SI (1) SI2640739T1 (es)
UA (1) UA112420C2 (es)
WO (2) WO2012066376A1 (es)
ZA (1) ZA201303042B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10632237B2 (en) 2006-10-09 2020-04-28 Minnetronix, Inc. Tangential flow filter system for the filtration of materials from biologic fluids
WO2012066376A1 (en) * 2010-11-18 2012-05-24 Centre National De La Recherche Scientifique - Cnrs - Inhibitors of apoptosis and uses thereof
GB201314610D0 (en) * 2013-08-15 2013-10-02 Blueberry Therapeutics Ltd Compounds and their uses
CN103585618B (zh) * 2013-10-31 2016-04-06 中山大学 端粒结合蛋白daxx在制备肿瘤细胞调控剂中的应用
CN108367102B (zh) 2015-08-05 2021-04-30 米奈特朗尼克斯有限公司 用于来自生物流体的物料的过滤的切向流过滤器系统
CN108472332B (zh) * 2015-11-13 2022-03-18 汉阳大学校产学协力团 用于通过经鼻施用来治疗中风的组合物
WO2019195693A1 (en) * 2018-04-05 2019-10-10 University Of Florida Research Foundation Polypeptide inhibitor of de novo lipogenesis in cancer cells
CN108753820A (zh) * 2018-06-07 2018-11-06 嘉兴学院 Daxx蛋白通过激活erk信号通路促进卵巢癌腹水细胞增殖和转移
CN112679595B (zh) * 2020-04-10 2022-11-01 南京市儿童医院 脑源肽或融合肽在新生儿缺氧缺血性脑损伤药物中的应用
JP2024530931A (ja) * 2021-08-06 2024-08-27 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ミスフォールドタンパク質の治療及び予防のための組成物及び方法
EP4691494A1 (en) * 2024-08-09 2026-02-11 Centre National de la Recherche Scientifique Inhibitors of endothelial apoptosis for use in the treatment of a condition due to microvascular injury

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034946A1 (en) * 1997-02-12 1998-08-13 Massachusetts Institute Of Technology Daxx, a novel fas-binding protein that activates jnk and apoptosis
DE60233137D1 (de) * 2001-02-16 2009-09-10 Univ R Transporter mit beabstandeten arginin-teilchen
RU2328273C2 (ru) * 2001-12-19 2008-07-10 Рисерч Дивелопмент Фаундейшн Липосомальная доставка соединений, основанных на витамине е
KR100597615B1 (ko) * 2004-05-07 2006-07-10 주식회사 동부한농 인간 ＮＨＥ1 이온채널 단백질 결합제로서의 인간Ｄａｘｘ 단백질 및 그의 단편
WO2010006177A2 (en) 2008-07-10 2010-01-14 Dana-Farber Cancer Institute, Inc. Muc1, caspase-8,and ded-containing proteins
WO2012066376A1 (en) * 2010-11-18 2012-05-24 Centre National De La Recherche Scientifique - Cnrs - Inhibitors of apoptosis and uses thereof

Also Published As

Publication number Publication date
MX2013005587A (es) 2014-02-03
KR20180119697A (ko) 2018-11-02
CN106188271B (zh) 2019-11-26
JP2013544249A (ja) 2013-12-12
UA112420C2 (uk) 2016-09-12
SG190681A1 (en) 2013-07-31
IL226005B (en) 2018-02-28
CL2013001411A1 (es) 2014-03-28
CO6700879A2 (es) 2013-06-28
ME02291B (me) 2016-02-20
DK2640739T3 (en) 2015-12-07
HRP20151165T1 (hr) 2015-12-18
KR101913285B1 (ko) 2018-10-30
CA2816827C (en) 2020-06-23
EA027336B1 (ru) 2017-07-31
EP2640739A2 (en) 2013-09-25
PL2640739T3 (pl) 2016-01-29
GEP201606514B (en) 2016-07-25
WO2012066376A1 (en) 2012-05-24
CA3078178C (en) 2023-07-11
KR102017645B1 (ko) 2019-09-03
KR20140032955A (ko) 2014-03-17
JP6204828B2 (ja) 2017-09-27
MA34670B1 (fr) 2013-11-02
EP2982685B1 (en) 2017-11-15
BR112013012362A2 (pt) 2016-08-30
ZA201303042B (en) 2014-07-30
RU2013127565A (ru) 2014-12-27
GT201300117A (es) 2015-11-13
IL257069B (en) 2019-09-26
HUE026150T2 (en) 2016-05-30
RS54422B1 (sr) 2016-04-28
PH12013500843A1 (en) 2013-06-24
AU2011331103B2 (en) 2016-11-24
IL226005A0 (en) 2013-06-27
MX345594B (es) 2017-02-07
EP2640739B1 (en) 2015-09-02
ES2653734T3 (es) 2018-02-08
SI2640739T1 (sl) 2016-01-29
EP2982685A1 (en) 2016-02-10
US9814758B2 (en) 2017-11-14
CA3078178A1 (en) 2012-05-22
CN103403023A (zh) 2013-11-20
EA201300592A1 (ru) 2013-10-30
CN103403023B (zh) 2016-08-17
ES2553770T3 (es) 2015-12-11
HK1184791A1 (zh) 2014-03-07
AU2011331103A1 (en) 2013-05-23
WO2012066103A3 (en) 2012-08-16
WO2012066103A2 (en) 2012-05-24
CR20130190A (es) 2013-10-07
US20130288979A1 (en) 2013-10-31
CN106188271A (zh) 2016-12-07
PT2640739E (pt) 2015-11-30
CA2816827A1 (en) 2012-05-22
IL257069A (en) 2018-03-29
MY170604A (en) 2019-08-20
RU2582247C2 (ru) 2016-04-20
NZ610620A (en) 2015-01-30
CY1118022T1 (el) 2017-05-17

Similar Documents

Publication Publication Date Title
NI201300045A (es) Inhibidores de apoptosis y usos de los mismos.
CL2012003226A1 (es) Compuestos derivados de 5-fluoro-1h-pirazolopiridina ; procedimiento de preparacion de estos; composicion framaceutica que los comprende; y su uso en el tratamiento de enfermedades cardiovasculares, sexuales y metabolicas.
ECSP12012349A (es) Agentes inductores de apoptosis contra el cáncer y de enfermedades inmunes y autoinmunes
ECSP12012348A (es) Agentes inductores de apoptosis contra el cáncer y de enfermedades inmunes y autoinmunes
BR112013031794A2 (pt) novos derivados de oxintomodulina e composição farmacêutica para o tratamento da obesidade compreendendo os mesmos
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
CO6680687A2 (es) Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CL2013002517A1 (es) Compuestos derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso en el tratamiento o profilaxis del cancer.
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
BR112015029386A8 (pt) uso de eribulina e lenvatinibe como terapia de combinação, composição farmacêutica compreendendo os mesmos e kit
CL2011003160A1 (es) Compuestos derivados de heterociclicos, moduladores cb2; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades reumaticas, autoinmune, inflamatorias, dolor, entre otras.
UY32937A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
MX2012000389A (es) Imidazoles fusionados y composiciones que los comprenden para el tratamiento de enfermedades parasitarias, tales como, por ejemplo, malaria.
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
BR112012002265A2 (pt) composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios
BR112015011759A2 (pt) composição simbiótica e uso da mesma
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
CL2011000168A1 (es) Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer.
CL2011002625A1 (es) Compuestos derivados de 3-(piridin-3-il-etinil)-piridina; preparaciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes.
UY33663A (es) Derivados amínicos para el tratamiento de trastornos proliferativos de la piel
CL2017000884A1 (es) Composición farmacéutica para usarse en el tratamiento o la prevención de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugía de derivación gástrica
CL2008000707A1 (es) Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.